A health economic analysis of clinical islet transplantation

Jessica Beckwith, John A Nyman, Brian Flanagan, Rudolf Schrover, Henk Jan Schuurman

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Islet cell transplantation is in clinical development for type 1 diabetes. There are no data on the cost in relationship to its benefits. We performed a cost-effectiveness analysis and made a comparison with standard insulin therapy, using Markov modeling and Monte Carlo simulations. The patient population was adults aged 20yr suffering from hypoglycemia unawareness. Data were estimates from literature and clinical trials: costs were based on the situation in the United States. For insulin therapy, cumulative cost per patient during a 20-yr follow-up was $663000, and cumulative effectiveness was 9.3 quality-adjusted life years (QALY), the average cost-effectiveness ratio being $71000 per QALY. Islet transplantation had a cumulative cost of $519000, a cumulative effectiveness of 10.9 QALY, and an average cost-effectiveness ratio of $47800. During the first 10yr, costs for transplantation were higher, but cumulative effectiveness was higher from the start onwards. In sensitivity analyses, the need for one instead of two transplants during the first year did not affect the conclusions, and islet transplantation remained cost-saving up to an initial cost of the procedure of $240000. This exploratory evaluation shows that islet cell transplantation is more effective than standard insulin treatment, and becomes cost-saving at about 9-10yr after transplantation.

Original languageEnglish (US)
Pages (from-to)23-33
Number of pages11
JournalClinical Transplantation
Issue number1
StatePublished - Jan 2012


  • Cost
  • Cost-effectiveness analysis
  • Economic model
  • Health economics
  • Islet cell transplantation


Dive into the research topics of 'A health economic analysis of clinical islet transplantation'. Together they form a unique fingerprint.

Cite this